Compare McKesson Corporation (MCK) vs 3M Company (MMM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs 3M Company — how do they compare? McKesson Corporation trades at $899.06 (market cap $102.58B), while 3M Company trades at $183.06 (market cap $93.88B). The key difference: McKesson Corporation and 3M Company are close in size by market cap, and 3M Company pays the higher dividend (1.71%). Which is the better fit depends on your goals.
| MCK | MMM | |
|---|---|---|
Market Cap | $102.58B | $93.88B |
Sector | Health | Industrials |
52-Week High | $995.69 | $183.13 |
52-Week Low | $659.01 | $141.10 |
Enterprise Value | $109.12B | $103.10B |
Dividend Yield | 0.43% | 1.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $869.58, down 0.14% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with revenue growth to $359.05B in 2025 and consistent earnings beats, including Q2 2026 EPS of $9.93 versus $9.56 expected. Valuation metrics like P/E of 23.33 and P/S of 0.26 indicate reasonable pricing relative to peers. Recent news highlights Q1 2027 results exceeding expectations and raised full-year guidance, driven by specialty drug and oncology growth.
Outlook remains positive with 80% analyst buy ratings and a $1,000 consensus price target, suggesting 15% upside. Risks include thin net margins of 1.12% and high liabilities at $76.83B, which could pressure equity during economic downturns. Investors should focus on execution of raised guidance and margin improvements from cost efficiencies.
3M (MMM) trades at $182.89, up 1.21% today, with a bullish technical signal from moving averages and strong support at $180. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $2.40 exceeding the $2.25 estimate, and raised its full-year guidance. Revenue for 2025 was $24.95 billion, with a net income margin of 11.9% and a high return on equity of 82.77%. Recent news highlights strength in the Safety & Industrial segment and a partnership with Microsoft on EBO technology.
The outlook is positive due to operational improvements and innovation, but risks include litigation liabilities and macroeconomic pressures. Analysts are mixed with a consensus price target of $173.00, below the current price, suggesting cautious optimism. The stock's valuation metrics, such as a P/E of 32.49, indicate it may be fully priced, requiring careful monitoring of execution against raised guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →
